Abstract
P179 - Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have